# Kiniksa Pharmaceuticals International, plc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Kiniksa Pharmaceuticals International, plc). ## Overview Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing therapies for diseases with unmet medical need, with emphasis on cardiovascular and inflammatory indications. Its only marketed product is ARCALYST, a biologic sold in the United States for recurrent pericarditis and certain rare autoinflammatory diseases, while its pipeline includes additional IL-1-related and immunology assets. ## Products & services • ARCALYST for recurrent pericarditis • ARCALYST for CAPS (FCAS and Muckle-Wells Syndrome) • ARCALYST for DIRA maintenance of remission • KPL-387 recurrent pericarditis program • KPL-1161 preclinical IL-1-related program • Other preclinical immunology/cardiovascular assets - **Commercial biologic product** (95%) — ARCALYST, the company's marketed IL-1 trap therapy sold in the U.S. through specialty pharmacies. - **Approved rare disease indications** (5%) — Approved uses of ARCALYST in recurrent pericarditis, CAPS, and DIRA that drive current sales. - **Clinical-stage pipeline** (0%) — KPL-387 and related programs being developed for recurrent pericarditis and other inflammatory diseases. - **Preclinical assets** (0%) — Earlier-stage immunology and cardiovascular programs such as KPL-1161 and other assets. - ARCALYST for recurrent pericarditis - ARCALYST for CAPS (FCAS and Muckle-Wells Syndrome) - ARCALYST for DIRA maintenance of remission - KPL-387 recurrent pericarditis program - KPL-1161 preclinical IL-1-related program - Other preclinical immunology/cardiovascular assets ## Customers Kiniksa sells primarily to a select network of third-party specialty pharmacies and logistics partners, which then dispense ARCALYST to patients by mail. Demand is driven by physicians treating rare inflammatory and cardiovascular diseases, while reimbursement depends on payors and insurers that determine access and coverage. Because the company has only one commercial product, customer concentration and channel execution are central to the business model. - **Specialty pharmacies** (primary) — They buy ARCALYST for distribution, patient support, and prescription fulfillment, making them the core commercial channel. - **Physicians and treatment centers** (primary) — Cardiologists, rheumatologists, and specialists prescribe ARCALYST for approved rare-disease indications. - **Patients with recurrent pericarditis** (primary) — Patients with painful inflammatory cardiovascular disease who need ongoing biologic treatment. - **Rare disease patients with CAPS or DIRA** (secondary) — Small patient groups using ARCALYST for approved orphan indications. - **Payors and insurers** (primary) — They do not buy the drug directly but determine reimbursement, coverage, and patient access. - Specialty pharmacies that purchase and dispense ARCALYST - Third-party logistics provider handling shipment and fulfillment - Physicians treating recurrent pericarditis and rare autoinflammatory disease - Patients needing chronic biologic therapy for small, defined populations - Government and private payors that influence access and reimbursement ## Geography The company is headquartered in the United States, with executive offices in Massachusetts and a registered office in London following its 2024 redomiciliation to the UK. Commercial revenue is currently generated almost entirely in the United States because ARCALYST is approved for sale only there. The company also maintains subsidiaries and tax presence in the UK, Switzerland, Germany, and France to support development, IP ownership, and international structuring. - **United States** (100%) — ARCALYST is currently approved for sale only in the U.S., so revenue is substantially all U.S.-based. - United States is the only commercial market for ARCALYST - Lexington, Massachusetts is the main operating base - London is the registered office after redomiciliation - UK, Switzerland, Germany, and France house subsidiaries and IP - International footprint supports development and tax structure ## Strategy Kiniksa's strategy is to expand ARCALYST commercialization in recurrent pericarditis while maintaining access and reimbursement support through its specialty pharmacy network. At the same time, it is advancing follow-on IL-1 and immunology programs to reduce dependence on a single product and broaden its long-term pipeline. Capital discipline remains important because the company expects continued spending on manufacturing, sales infrastructure, and clinical development. - **Grow ARCALYST in recurrent pericarditis** (short-term) — It is the company's only commercial product and main revenue driver. - **Maintain access and reimbursement** (short-term) — Rare-disease demand depends on coverage, pricing, and specialty pharmacy execution. - **Advance pipeline diversification** (medium-term) — A broader pipeline reduces single-product dependence and supports future growth. - Expand ARCALYST adoption in recurrent pericarditis - Protect reimbursement and patient access through specialty channels - Advance KPL-387 and other pipeline assets - Build commercial and medical infrastructure for rare disease launches - Use licensing and strategic transactions to extend pipeline optionality ## Risks The company is highly dependent on ARCALYST, so any slowdown in uptake, reimbursement pressure, or competitive entry could materially affect revenue. Its business also relies on third parties for manufacturing, logistics, and specialty pharmacy distribution, which creates supply and execution risk in a regulated biologics market. Clinical development, regulatory approval, and the ability to fund operations remain important risks because the pipeline is still early and the company may need additional capital. - **Dependence on ARCALYST commercialization** [high] — The company has one marketed product, so any demand or access disruption can materially affect revenue. - **Third-party manufacturing and supply chain reliance** [high] — Commercial and clinical supply are outsourced, and biologic inputs can be scarce or single-sourced. - **Reimbursement and payor pressure** [medium] — Coverage and pricing decisions directly affect patient access and net revenue realization. - **Competition in IL-1 and inflammatory diseases** [medium] — Other drugs may offer more convenient dosing or alternative mechanisms in the same indications. - Single-product dependence on ARCALYST - Specialty pharmacy and logistics execution risk - Competition in CAPS, DIRA, and recurrent pericarditis - Manufacturing and raw-material supply constraints - Need for additional capital if pipeline spending rises ## Accounting Revenue is recognized at a point in time when ARCALYST is shipped and control passes to the customer, but reported net revenue is reduced by rebates, chargebacks, returns, copay assistance, and specialty pharmacy fees. Because the company sells through a narrow channel and serves small patient populations, estimates for variable consideration and quarterly demand can materially affect reported revenue. Investors should also watch accrued R&D expenses, uncertain tax positions, and deferred tax asset realizability, which depend on management estimates and future profitability assumptions. - **Revenue recognition and variable consideration** — Can move quarterly revenue and gross-to-net margins. - **Accrued research and development expenses** — Affects operating expense timing and comparability. - **Deferred tax assets and uncertain tax positions** — Can affect tax expense and balance sheet valuation allowances. - Point-in-time revenue recognition on shipment - Net revenue reduced by rebates, chargebacks, returns, and copay support - Small patient base makes variable consideration estimates sensitive - Accrued R&D expenses depend on clinical and vendor estimates - Deferred tax asset realizability depends on future taxable income --- *Last updated: 2026-04-28T20:20:23.462688+00:00*